Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

Raymond James ups Eupraxia PT on new osteoarthritis data

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $17 (Canadian) from $11, maintaining a “strong buy” rating, after the company reported positive Phase 2b data with EP-104IAR for pain...

June 27, 2023

Markets

Cantor starts AVITA Medical at OW; PT $23

Cantor Fitzgerald launched coverage of AVITA Medical (NASDAQ:RCEL) with an “overweight” rating and $23 target price. The stock closed at $15.71 on June 26. Avita is a regenerative medicine company commercializing its...

June 27, 2023

Executive Moves

iBio names Dr. Martin Brenner and Felipe Duran as permanent CEO and CFO, respectively

iBio (NYSEA:IBIO) appointed Martin Brenner, DVM, Ph.D., as CEO and Felipe Duran as CFO, effective immediately. Dr. Brenner will also continue to serve as iBio’s CSO, a role he has held since December 2020. The...

June 27, 2023

Markets

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

Research Capital raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $25 (Canadian) from $10.30 and maintained a “speculative buy” rating after the company reported positive results from its Phase 2b...

June 26, 2023

Developments

FDA lifts clinical hold on deucrictibant for on-demand treatment of HAE

The FDA lifted the clinical hold on Pharvaris’ (NASDAQ:PHVS) IND application for deucrictibant for the on-demand treatment of hereditary angioedema (HAE) following a review of data from a preplanned interim analysis of...

June 26, 2023

Developments

Tonix to acquire 2 FDA-approved migraine products from Upsher-Smith Labs

Tonix Pharmaceuticals (NASDAQ:TNXP) agreed to acquire two currently-marketed products from Upsher-Smith Laboratories: Zembrace SymTouch injection 3 mg, and Tosymra nasal spray 10 mg, for the treatment of acute migraine...

June 26, 2023

Markets

restor3d to acquire Conformis for $2.27 a share

Closely-held restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of Conformis (NASDAQ:CFMS) for $2.27 a share, which represents an approximate 96% premium to the closing...

June 23, 2023

Markets

Raymond James starts Fusion Pharma at OP; PT $13

Raymond James initiated coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with an “outperform” rating and $13 price target. The stock closed at $4.37 on June 22. Fusion is a precision oncology company that has built a...

June 23, 2023

Developments

Talaris Therapeutics to merge with Tourmaline Bio

Talaris Therapeutics (NASDAQ:TALS) and closely-held Tourmaline Bio agreed to merge in an all-stock transaction. The combined company will focus on advancing Tourmaline’s lead program, TOUR006, a potentially best-in...

June 22, 2023

Developments

FDA lifts clinical hold on DiaMedica ischemic stroke trial

The FDA has removed a clinical hold placed on DiaMedica’s (NASDAQ:DMAC) investigational new drug application for its ReMEDy2 Phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and...

June 21, 2023

Developments

Annovis Bio gets positive DSMB review of Phase 3 PD trial

A Data and Safety Monitoring Board (DSMB) recommended that Annovis Bio (NYSE:ANVS) continue its Phase 3 trial as originally designed of buntanetap, a drug for early Parkinson’s disease (PD) patients. The DSMB decision...

June 20, 2023

Markets

Quipt Home Medical up-lists to TSX

Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) received final approval to list its common shares on the Toronto Stock Exchange and will commence trading on the TSX at the market open on June 21 under the symbol, QIPT. With...

June 20, 2023

Raymond James ups Eupraxia PT on new osteoarthritis data

Cantor starts AVITA Medical at OW; PT $23

iBio names Dr. Martin Brenner and Felipe Duran as permanent CEO and CFO, respectively

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

FDA lifts clinical hold on deucrictibant for on-demand treatment of HAE

Tonix to acquire 2 FDA-approved migraine products from Upsher-Smith Labs

restor3d to acquire Conformis for $2.27 a share

Raymond James starts Fusion Pharma at OP; PT $13

Talaris Therapeutics to merge with Tourmaline Bio

FDA lifts clinical hold on DiaMedica ischemic stroke trial

Annovis Bio gets positive DSMB review of Phase 3 PD trial

Quipt Home Medical up-lists to TSX

General

More